2018
DOI: 10.1002/art.40466
|View full text |Cite
|
Sign up to set email alerts
|

Subcutaneous Abatacept in Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis

Abstract: ObjectiveTo investigate the pharmacokinetics, effectiveness, and safety of subcutaneous (SC) abatacept treatment over 24 months in patients with polyarticular‐course juvenile idiopathic arthritis (JIA).MethodsIn this phase III, open‐label, international, multicenter, single‐arm study, patients with polyarticular JIA (cohort 1, ages 6–17 years and cohort 2, ages 2–5 years) in whom treatment with ≥1 disease‐modifying antirheumatic drug was unsuccessful received weight‐tiered SC abatacept weekly: 10 to <25 kg (50… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
75
0
1

Year Published

2020
2020
2023
2023

Publication Types

Select...
6

Relationship

4
2

Authors

Journals

citations
Cited by 55 publications
(77 citation statements)
references
References 29 publications
1
75
0
1
Order By: Relevance
“…A safety summary of cohort 2 is presented in Table 3. Abatacept safety profile was consistent between age cohorts [6]. Related serious adverse events (SAEs), SAEs and related AEs were reported in a higher proportion of patients who participated versus those who did not participate in this substudy.…”
Section: Safetymentioning
confidence: 60%
See 4 more Smart Citations
“…A safety summary of cohort 2 is presented in Table 3. Abatacept safety profile was consistent between age cohorts [6]. Related serious adverse events (SAEs), SAEs and related AEs were reported in a higher proportion of patients who participated versus those who did not participate in this substudy.…”
Section: Safetymentioning
confidence: 60%
“…This substudy of a 24-month, Phase III trial (NCT01844518) of SC abatacept in patients (cohort 1: 173 patients aged 6-17 years; cohort 2: 46 patients aged 2-5 years) with active pJIA and inadequate response/intolerance to ≥1 DMARD [6] was conducted across 48 centers worldwide by members of the Paediatric Rheumatology International Trials Organisation [10] and the Pediatric Rheumatology Collaborative Study Group [11]. Patients received weight-tiered weekly SC abatacept (10-< 25 kg [50 mg], 25-< 50 kg [87.5 mg]) for 4 months.…”
Section: Study Design and Patient Populationmentioning
confidence: 99%
See 3 more Smart Citations